Arrowhead Pharmaceuticals Inc.
ARWR
Market Cap$2.8B
Close$
$-24.51
212.1% downside
Current Fair Value
212.1% downsideOvervalued by 212.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.80 Billion |
|---|---|
| Enterprise Value | $2.58 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-2.77 |
| Beta | 1.03 |
| Outstanding Shares | 123,896,914 |
| Avg 30 Day Volume | 836,465 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -9.44 |
|---|---|
| PEG | -4.26 |
| Price to Sales | 21.87 |
| Price to Book Ratio | 21.87 |
| Enterprise Value to Revenue | 14.2 |
| Enterprise Value to EBIT | -8.62 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Arrowhead Pharmaceuticals Inc.
CEO: Christopher Anzalone